Intracellular uptake of EGCG-loaded deformable controlled release liposomes for skin cancer

M. Marwah, Y. Perrie, R. K.S. Badhan, D. Lowry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Caucasian population groups have a higher propensity to develop skin cancer, and associated clinical interventions often present substantial financial burden on healthcare services. Conventional treatments are often not suitable for all patient groups as a result of poor efficacy and toxicity profiles. The primary objective of this study was to develop a deformable liposomal formulation, the properties of which being dictated by the surfactant Tween 20, for the dermal cellular delivery of epigallocatechin gallatein (EGCG), a compound possessing antineoplastic properties. The results demonstrated a significant (p ≤ 0.05) decrease in liposome deformability index (74 ± 8 to 37 ± 7) as Tween 20 loading increased from 0 to 10% w/w, indicating an increase in elasticity. EGCG release over 24-h demonstrated Tween 20 incorporation directly increased release from 13.7% ± 1.1% to 94.4% ± 4.9% (for 0 and 10% w/w Tween 20 respectively). Finally, we demonstrated DilC-loaded deformable liposomes were localized intracellularly within human dermal fibroblast and keratinocyte cells within 2 h. Thus, it was evident that deformable liposomes may aid drug penetration into dermal cells and would be useful in developing a controlled-release formulation.

Original languageEnglish
JournalJournal of Liposome Research
Early online date9 May 2019
DOIs
Publication statusE-pub ahead of print - 9 May 2019

    Fingerprint

Keywords

  • controlled release
  • deformable liposomes
  • dermal release
  • elastic liposomes
  • Skin cancer

Cite this